UBX
FY2029 EPS Estimate
$0.13
FY2029E EPS$0.13

Analyst Sentiment

Wall St. Consensus
Buy
10 analysts·Moderate coverage
68
Score
7 Buy (70%)3 Hold (30%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
770%
Hold
330%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$1.00
+399.8%
Consensus
$2.50
+1149.4%
Bull
$4.00
+1899.0%
12-Month Target Range10 analysts
$1.00$2.50$4.00
Current $0.20Consensus
Current Price
$0.20
Upside to Consensus
$2.30

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+220.80%
EPS
FY2028
Rev-56.85%
EPS
FY2029
Rev+83.93%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029E
Revenue Avg$6M$20M$9M$16M
Low$6M$20M$9M$16M
High$6M$20M$9M$16M
EBITDA Avg$1M$4M$2M$3M
Low$1M$4M$2M$3M
High$1M$4M$2M$3M
EBIT Avg$1M$4M$2M$3M
Low$1M$4M$2M$3M
High$1M$4M$2M$3M
Net Income Avg$-14M$-10M$-925,487$2M
Low$-17M$-10M$-925,487$2M
High$-11M$-10M$-925,487$2M
EPS Avg$-0.82$-0.57$-0.06$0.13
Low$-1.00$-0.57$-0.06$0.13
High$-0.68$-0.57$-0.06$0.13
Analysts (Rev / EPS)4 / 33 / 11 / 12 / 1

Earnings Surprises

Recent Analyst Actions

May 16, 2025Mizuho Securities
Unity Biotechnology downgraded to Neutral from Outperform at Mizuho
Target:$1.00
+22.0%from $0.82
Mar 25, 2025Chardan Capital
Unity Biotechnology price target lowered to $4 from $6 at Chardan
Target:$4.00
+217.5%from $1.26
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.